Overview
- Isomorphic Labs secured $2.1 billion in Series B funding led by Thrive Capital with participation from Alphabet, GV, CapitalG, MGX, Temasek and the UK Sovereign AI Fund.
- The raise ranks among the largest for an AI drug discovery company, signaling strong confidence in the approach.
- The company plans to use the funds to expand its AI platform, advance more drug programs toward clinical stages and hire across AI, biology and engineering.
- IsoDDE, the firm’s unified drug design engine, builds on AlphaFold to predict molecular structures, how drugs bind to targets and potential toxic effects across multiple drug types.
- The company now targets its first clinical trials by the end of 2026 after previously aiming for the end of 2025.